Category: Federal Forum Posters
Purpose: Metabolic adverse effects including weight, glucose, lipid, and blood pressure alterations are major concerns with second-generation antipsychotics (SGAs). A consensus statement published in 2004 is the most commonly followed recommendation regarding monitoring for these complications. Current literature suggests adequate monitoring of SGAs is rarely achieved. An electronic monitoring tool, referred to as a reminder, was implemented at this facility to alert providers of gaps in adherence to these recommendations. Providers can complete this reminder after obtaining appropriate monitoring. The objective of this project is to evaluate the percent utilization of the tool, assess if monitoring was performed, and address discrepancies.
Methods: This quality improvement project will be approved by the Pharmacy and Therapeutics Committee prior to implementation and IRB approval is not required. A database will be used to identify patients without a completed SGA reminder at our facility. A chart review will then be conducted to determine if gaps between reminder completion and confirmed assessment exist. The percent utilization of the tool and number of patients without a reminder completed who received appropriate monitoring will be determined. Patients without a completed SGA reminder who did not receive appropriate monitoring will be assigned to a clinical pharmacist. During a four-month intervention window, these patients will be contacted with the offer to complete recommended assessments and provided with education regarding monitoring of SGAs. A follow-up chart review will be performed following the intervention period to evaluate changes in percent utilization of the tool and fulfillment of monitoring recommendations. Results will be analyzed using descriptive statistics.
Results: not applicable
Conclusion: not applicable
Steven Shofner– Resident, Sheridan VA Healthcare System, Sheridan, WY